SillaJen
SillaJen is a global leader in oncolytic immunotherapeutics, focusing on targeting, attacking, and eradicating cancers through innovative platforms and pipelines. The company develops and commercializes cancer-targeted oncolytic viruses, with a strong emphasis on research, clinical trials, and strategic partnerships worldwide. Their lead product, Pexa-Vec (JX-594), is an oncolytic vaccinia virus engineered for cancer therapy, demonstrating mechanisms such as infecting and lysing tumor cells, disrupting tumor vasculature, and stimulating immune responses. SillaJen's pipeline includes various oncolytic virus candidates in different stages of development, targeting solid tumors, renal cell carcinoma, melanoma, and prostate cancer.
Industries
Nr. of Employees
medium (51-250)
SillaJen
3rd Floor, 106 Cheonggyecheon-ro, Jung-gu, Seoul (ZIP Code : 04542)
Patents
Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof
US-10646524-B2
View DetailsGeneration of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
US-10434169-B2
View Details
Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof
US-10646524-B2
View DetailsGeneration of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
US-10434169-B2
View DetailsProducts
Clinical-stage oncolytic vaccinia therapeutic candidate (clinical-stage, intravenous and intratumoral delivery)
Recombinant vaccinia-based oncolytic therapeutic candidate engineered for tumor-selective replication via targeted genetic modifications and for expression of immunostimulatory transgenes; evaluated in multiple clinical studies and route-of-administration assessments.
Next-generation oncolytic vaccinia candidate series (preclinical)
Preclinical oncolytic vaccinia candidates engineered for enhanced tumor selectivity via targeted viral gene deletions and designed to carry immunostimulatory payloads; reported preclinical evidence of tumor debulking and platform patent activity.
Clinical-stage oncology development candidate (non-viral modality)
Clinical-stage oncology development candidate acquired or in-licensed for evaluation in solid tumors and hematologic indications and being tested in combination regimens in sponsor-initiated studies.
Preclinical oncolytic virus platform series
Platform-derived preclinical oncolytic virus candidates intended for development in solid tumors with reported preclinical support and platform-level patenting activity.
Clinical-stage oncolytic vaccinia therapeutic candidate (clinical-stage, intravenous and intratumoral delivery)
Recombinant vaccinia-based oncolytic therapeutic candidate engineered for tumor-selective replication via targeted genetic modifications and for expression of immunostimulatory transgenes; evaluated in multiple clinical studies and route-of-administration assessments.
Next-generation oncolytic vaccinia candidate series (preclinical)
Preclinical oncolytic vaccinia candidates engineered for enhanced tumor selectivity via targeted viral gene deletions and designed to carry immunostimulatory payloads; reported preclinical evidence of tumor debulking and platform patent activity.
Clinical-stage oncology development candidate (non-viral modality)
Clinical-stage oncology development candidate acquired or in-licensed for evaluation in solid tumors and hematologic indications and being tested in combination regimens in sponsor-initiated studies.
Preclinical oncolytic virus platform series
Platform-derived preclinical oncolytic virus candidates intended for development in solid tumors with reported preclinical support and platform-level patenting activity.
Services
Sponsor and collaborator support for design and execution of sponsor-initiated and investigator-initiated clinical trials across multiple countries, including combination therapy studies and site coordination.
Coordination with contract manufacturing organizations for manufacturing, quality systems, and process development to support clinical and commercial supply of viral therapeutics.
Centralized handling of global clinical development, regulatory filings, and manufacturing-related quality oversight through a regional operating entity to facilitate international program management.
Sponsor and collaborator support for design and execution of sponsor-initiated and investigator-initiated clinical trials across multiple countries, including combination therapy studies and site coordination.
Coordination with contract manufacturing organizations for manufacturing, quality systems, and process development to support clinical and commercial supply of viral therapeutics.
Centralized handling of global clinical development, regulatory filings, and manufacturing-related quality oversight through a regional operating entity to facilitate international program management.
Expertise Areas
- Oncolytic virotherapy development
- Viral vector engineering
- Clinical trial management (Phase I–III, multisite)
- Combination immunotherapy development
Key Technologies
- Oncolytic vaccinia virus engineering
- Targeted viral gene deletion and transgene insertion
- Intravenous and intratumoral delivery of viral therapeutics
- Assays for tumor-associated vasculature disruption